JPWO2016195070A1 - 還元型グルタチオンのα型結晶の製造方法及び当該結晶の保存方法 - Google Patents
還元型グルタチオンのα型結晶の製造方法及び当該結晶の保存方法 Download PDFInfo
- Publication number
- JPWO2016195070A1 JPWO2016195070A1 JP2017522276A JP2017522276A JPWO2016195070A1 JP WO2016195070 A1 JPWO2016195070 A1 JP WO2016195070A1 JP 2017522276 A JP2017522276 A JP 2017522276A JP 2017522276 A JP2017522276 A JP 2017522276A JP WO2016195070 A1 JPWO2016195070 A1 JP WO2016195070A1
- Authority
- JP
- Japan
- Prior art keywords
- reduced glutathione
- crystal
- type
- crystals
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 275
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 196
- 108010024636 Glutathione Proteins 0.000 title claims abstract description 189
- 238000000034 method Methods 0.000 title claims abstract description 43
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 20
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 94
- 238000002425 crystallisation Methods 0.000 claims abstract description 60
- 239000007864 aqueous solution Substances 0.000 claims abstract description 59
- 230000008025 crystallization Effects 0.000 claims abstract description 59
- 230000007704 transition Effects 0.000 claims abstract description 33
- -1 aliphatic amino acids Chemical class 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 150000001413 amino acids Chemical class 0.000 claims abstract description 22
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 13
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000011593 sulfur Substances 0.000 claims abstract description 12
- 238000003860 storage Methods 0.000 abstract description 10
- 230000002829 reductive effect Effects 0.000 abstract description 4
- 229940024606 amino acid Drugs 0.000 description 41
- 235000001014 amino acid Nutrition 0.000 description 41
- 239000000243 solution Substances 0.000 description 24
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 20
- 229960003767 alanine Drugs 0.000 description 19
- 108010053070 Glutathione Disulfide Proteins 0.000 description 18
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 18
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 17
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 17
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 13
- JQDFGZKKXBEANU-IMJSIDKUSA-N Ala-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](CS)C(O)=O JQDFGZKKXBEANU-IMJSIDKUSA-N 0.000 description 10
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 5
- 229930182820 D-proline Natural products 0.000 description 5
- 235000013878 L-cysteine Nutrition 0.000 description 5
- 239000004201 L-cysteine Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 238000002834 transmittance Methods 0.000 description 5
- 229960004799 tryptophan Drugs 0.000 description 5
- 238000001816 cooling Methods 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 229960005190 phenylalanine Drugs 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- RITKHVBHSGLULN-WHFBIAKZSA-N L-gamma-glutamyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(O)=O RITKHVBHSGLULN-WHFBIAKZSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 108010068906 gamma-glutamylcysteine Proteins 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
- C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
[1]脂肪族アミノ酸、含硫アミノ酸、芳香族アミノ酸、類縁化合物及びジペプチドからなる群より選択される少なくとも1つの化合物からなる、還元型グルタチオンのβ型結晶の発生及び/又は還元型グルタチオンのα型結晶からβ型結晶への転移を抑制するための媒晶剤。
[2]上記[1]記載の媒晶剤を含有する、還元型グルタチオンのα型結晶。
[3]媒晶剤の含有量が、還元型グルタチオンのα型結晶に対して0.01〜10重量%である、上記[2]記載の結晶。
[4]還元型グルタチオンを含有する水溶液に、上記[1]記載の媒晶剤を添加する工程、及び還元型グルタチオンのα型結晶を晶析させる工程を含む、還元型グルタチオンのα型結晶の製造方法。
[5]媒晶剤の添加量が、還元型グルタチオンに対して0.01〜10重量%である、上記[4]記載の方法。
[6]還元型グルタチオンの水溶液に、上記[1]記載の媒晶剤を添加する工程を含む、還元型グルタチオンの水溶液の保存方法。
[7]媒晶剤の添加量が、還元型グルタチオンに対して0.01〜10重量%である、上記[6]記載の方法。
[8]還元型グルタチオンのα型結晶に、上記[1]記載の媒晶剤を添加する工程を含む、還元型グルタチオンのα型結晶の保存方法。
[9]媒晶剤の添加量が、還元型グルタチオンに対して0.01〜10重量%である、上記[8]記載の方法。
(定義)
(本発明の還元型グルタチオン水溶液の保存方法)
カラム:Inertsil ODS−3 内径3.0mm、長さ150mm
カラム温度:35℃
検出器:UV検出器 波長210nm
移動相組成:1−ヘプタンスルホン酸ナトリウム/リン酸二水素カリウム/リン酸/メタノール
(本発明の還元型グルタチオンのα型結晶)
カラム:YMC Triart C18 内径3.0mm、長さ150mm
カラム温度:40℃
検出器:蛍光検出器 励起波長360nm/蛍光波長440nm
移動相組成:クエン酸三ナトリウム二水和物/無水硫酸ナトリウム/n−プロパノール/ラウリル硫酸ナトリウム
(本発明の還元型グルタチオンのα型結晶の保存方法)
カラム:YMC Triart C18 内径3.0mm、長さ150mm
カラム温度:40℃
検出器:蛍光検出器 励起波長360nm/蛍光波長440nm
移動相組成:クエン酸三ナトリウム二水和物/無水硫酸ナトリウム/n−プロパノール/ラウリル硫酸ナトリウム
(本発明の還元型グルタチオンのα型結晶の製造方法)
還元型グルタチオンのα型結晶の保存時における媒晶剤の添加によるβ型結晶への転移抑制効果の確認試験
還元型グルタチオンのα型結晶の保存時における媒晶剤の添加によるβ型結晶の発生抑制効果の確認試験
還元型グルタチオン水溶液の保存時における媒晶剤の添加効果の確認試験
還元型グルタチオン水溶液の保存時のβ型結晶の発生の抑制に必要な媒晶剤の添加量の検討
還元型グルタチオンのα型結晶の製造方法(1)
還元型グルタチオンのα型結晶の製造方法(2)
L−アラニン又はL−システインをそれぞれ10重量%添加して晶析させることにより取得した結晶は、共に粉末X線回折において、回折角2θが、6.3°、12.6°、13.8°、16.2°、22.3°、25.7°、30.1°、31.9°、32.0°及び33.5°にピークを有する還元型グルタチオンのα型結晶であることが分かった。
Claims (9)
- 脂肪族アミノ酸、含硫アミノ酸、芳香族アミノ酸、類縁化合物及びジペプチドからなる群より選択される少なくとも1つの化合物からなる、還元型グルタチオンのβ型結晶の発生及び/又は還元型グルタチオンのα型結晶からβ型結晶への転移を抑制するための媒晶剤。
- 請求項1記載の媒晶剤を含有する、還元型グルタチオンのα型結晶。
- 媒晶剤の含有量が、還元型グルタチオンのα型結晶に対して0.01〜10重量%である、請求項2記載の結晶。
- 還元型グルタチオンを含有する水溶液に、請求項1記載の媒晶剤を添加する工程、及び還元型グルタチオンのα型結晶を晶析させる工程を含む、還元型グルタチオンのα型結晶の製造方法。
- 媒晶剤の添加量が、還元型グルタチオンに対して0.01〜10重量%である、請求項4記載の方法。
- 還元型グルタチオンの水溶液に、請求項1記載の媒晶剤を添加する工程を含む、還元型グルタチオンの水溶液の保存方法。
- 媒晶剤の添加量が、還元型グルタチオンに対して0.01〜10重量%である、請求項6記載の方法。
- 還元型グルタチオンのα型結晶に、請求項1記載の媒晶剤を添加する工程を含む、還元型グルタチオンのα型結晶の保存方法。
- 媒晶剤の添加量が、還元型グルタチオンに対して0.01〜10重量%である、請求項8記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015114855 | 2015-06-05 | ||
JP2015114855 | 2015-06-05 | ||
PCT/JP2016/066586 WO2016195070A1 (ja) | 2015-06-05 | 2016-06-03 | 還元型グルタチオンのα型結晶の製造方法及び当該結晶の保存方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021021715A Division JP7577557B2 (ja) | 2015-06-05 | 2021-02-15 | 還元型グルタチオンのα型結晶の製造方法及び当該結晶の保存方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2016195070A1 true JPWO2016195070A1 (ja) | 2018-03-22 |
JP6868556B2 JP6868556B2 (ja) | 2021-05-12 |
Family
ID=57441284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017522276A Active JP6868556B2 (ja) | 2015-06-05 | 2016-06-03 | 還元型グルタチオンのα型結晶の製造方法及び当該結晶の保存方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10407463B2 (ja) |
EP (2) | EP3305801A4 (ja) |
JP (1) | JP6868556B2 (ja) |
CN (1) | CN107636006B (ja) |
WO (1) | WO2016195070A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017159555A1 (ja) | 2016-03-17 | 2017-09-21 | 協和発酵バイオ株式会社 | 還元型グルタチオンの結晶及びその製造方法 |
CN113754717A (zh) * | 2021-10-15 | 2021-12-07 | 南京高新工大生物技术研究院有限公司 | 一种还原型谷胱甘肽α型晶体的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61282397A (ja) * | 1985-06-07 | 1986-12-12 | Kohjin Co Ltd | グルタチオン及びγ−グルタミルシステインの精製法 |
JPH05339286A (ja) * | 1992-06-10 | 1993-12-21 | Kazuoki Ishihara | 還元型グルタチオンの安定化法および安定化組成物 |
JP2010059125A (ja) * | 2008-09-05 | 2010-03-18 | Ajinomoto Co Inc | シトルリンの晶析方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52131528A (en) | 1976-04-28 | 1977-11-04 | Kyowa Hakko Kogyo Co Ltd | Production of glutathione of reduced type |
CN104693269A (zh) | 2006-10-16 | 2015-06-10 | 协和发酵生化株式会社 | 谷胱甘肽的结晶及其制造方法 |
JP6081906B2 (ja) | 2013-12-12 | 2017-02-15 | 日本電信電話株式会社 | 議論支援装置および議論支援プログラム |
-
2016
- 2016-06-03 EP EP16803501.2A patent/EP3305801A4/en not_active Withdrawn
- 2016-06-03 CN CN201680032873.8A patent/CN107636006B/zh active Active
- 2016-06-03 WO PCT/JP2016/066586 patent/WO2016195070A1/ja active Application Filing
- 2016-06-03 JP JP2017522276A patent/JP6868556B2/ja active Active
- 2016-06-03 EP EP24165107.4A patent/EP4406960A2/en active Pending
- 2016-06-03 US US15/579,592 patent/US10407463B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61282397A (ja) * | 1985-06-07 | 1986-12-12 | Kohjin Co Ltd | グルタチオン及びγ−グルタミルシステインの精製法 |
JPH05339286A (ja) * | 1992-06-10 | 1993-12-21 | Kazuoki Ishihara | 還元型グルタチオンの安定化法および安定化組成物 |
JP2010059125A (ja) * | 2008-09-05 | 2010-03-18 | Ajinomoto Co Inc | シトルリンの晶析方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2021080265A (ja) | 2021-05-27 |
EP4406960A2 (en) | 2024-07-31 |
CN107636006B (zh) | 2021-11-09 |
EP3305801A4 (en) | 2019-01-23 |
CN107636006A (zh) | 2018-01-26 |
WO2016195070A1 (ja) | 2016-12-08 |
EP3305801A1 (en) | 2018-04-11 |
US20180170959A1 (en) | 2018-06-21 |
US10407463B2 (en) | 2019-09-10 |
JP6868556B2 (ja) | 2021-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | Effect of sodium chloride on the nucleation and polymorphic transformation of glycine | |
Kaptein et al. | Attrition‐enhanced deracemization of an amino acid derivative that forms an epitaxial racemic conglomerate | |
JP6868556B2 (ja) | 還元型グルタチオンのα型結晶の製造方法及び当該結晶の保存方法 | |
EP3150623B1 (en) | Solvate of cyclic peptide compound, preparation method for same, and uses thereof | |
JPWO2016121810A1 (ja) | N−アセチルノイラミン酸アンモニウム塩・無水和物の結晶及びその製造方法 | |
JPWO2008102469A1 (ja) | 蛋白質結晶化剤および蛋白質結晶化剤を用いた蛋白質結晶化方法 | |
Sun et al. | Additive-assisted preferential crystallization of racemic component: A case of norvaline | |
JP7577557B2 (ja) | 還元型グルタチオンのα型結晶の製造方法及び当該結晶の保存方法 | |
US7820860B2 (en) | Method for separating compound-forming chiral systems | |
O'Mahony et al. | Investigating the dissolution of the metastable triclinic polymorph of carbamazepine using in situ microscopy | |
Elfassy et al. | Crystallization of amino acids at the chiral ionic liquid/water interface | |
ES2969457T3 (es) | Método para preparar un diastereómero de un derivado del ácido cítrico | |
Chen et al. | Pasteur revisited: chiral separation by crystallization on self-assembled monolayers | |
Pons-Siepermann et al. | Purification of nitrophenols using complex-assisted crystallization | |
JP5125908B2 (ja) | シトルリンの晶析方法 | |
Dhanasekaran et al. | Nucleation control, separation and bulk growth of metastable α-l-glutamic acid single crystals in the presence of l-tyrosine | |
JPS59227848A (ja) | ポリペプチド類の製造方法 | |
JP6716903B2 (ja) | ジペプチドの製造方法 | |
Sato et al. | New optical resolution method for racemic DL-aspartic acid by crystallization in the presence of d-or l-asparagine as a tailor-made additive | |
CN104592046B (zh) | 光学活性的缬氨酸复合物及其生产方法 | |
Yang et al. | Ternary phase diagram and the formation mechanism of two distinct solid solutions of amino acid systems: L-Valine/L-norvaline and L-valine/L-alanine | |
HRP20020122A2 (en) | Methods for crystallization of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine n-carboxyanhydride | |
Abd Rahim et al. | Screening of carbamazepine-ibuprofen co-crystal formation using non-stoichiometric and stoichiometric methods | |
Sinha et al. | Co-crystallization as a Versatile Tool in Separations Technology | |
JP5200245B2 (ja) | Dl−バリンラセミ化合物の光学分割方法。 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180109 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20180410 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20180502 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20180413 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190410 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200602 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200731 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20201215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210215 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210215 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210225 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210302 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210406 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210412 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6868556 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |